University of Nebraska Medical Center, Omaha, NE
Linda My Huynh , Olivia Taylor , Jacob Marasco , Shuo Wang , Michael Baine
Background: mpMRI-derived radiomic features have been shown to capture sub-visual patterns for quantitative characterization of tumor phenotype. We seek to compare the diagnostic performance of a mpMRI-based radiomic model to currently available nomograms for prediction of post-radical prostatectomy (RP) biochemical recurrence (BCR). Methods: mpMRI was obtained from 76 patients who had underwent RP for treatment of localized PCa. All patients had ≥2 years follow-up and those with neo-adjuvant or adjuvant treatment were excluded. Radiomic analysis and cross-validation of mpMRI features yielded features significantly correlated with BCR, defined as two consecutive serum PSA≥0.2ng/ml. These features were aggregated to construct a radiomic model, which was compared to the risk scores generated by inputting patients’ clinicodemographic features into the USCF Cancer of the Prostate Risk Assessment (UCSF-CAPRA) score and Memorial Sloan Kettering Cancer Center (MSKCC) Pre-Radical Prostatectomy nomogram. The performance of each model was compared utilizing receiver-operator curve (ROC) analysis and area under the curve (AUC) was reported. Results: In feature extraction and ranking, six radiomic features were determined to be important and non-redundant in predicting PCa recurrence (least material condition, gray-level non-uniformity, shape-elongation, shape-sphericity, first-order skewness). These features were aggregated into the radiomic model and repeated five-fold cross validation yielded a model with AUC of 0.95±0.06, 33% sensitivity, and 100% specificity. UCSF-CAPRA and MSKCC nomograms yielded AUC of 0.72±0.07 and 0.82±0.07, respectively. Conclusions: The mpMRI-derived radiomic model performed well when compared to the UCSF-CAPRA score and MSKCC Pre-Radical Prostatectomy nomogram. Future projects will incorporate patient demographics and disease characteristics available at the time of initial PCa diagnosis to improve the radiomic model accuracy.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2021 Genitourinary Cancers Symposium
First Author: Tian Zhang
2023 ASCO Annual Meeting
First Author: Tian Zhang
2023 ASCO Annual Meeting
First Author: Nasreen Khan
2023 ASCO Genitourinary Cancers Symposium
First Author: Linda My Huynh